The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Carl Zeiss Meditec AG accounts for 4.77 % of our European Portfolio. A trade is currently open since 05/03/2019 with a purchase price of € 86.90. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The group usually releases upbeat results with huge surprise rates.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 73.95 EUR
Stock prices approach a strong long-term resistance in weekly data at EUR 89.55.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.48 times its estimated earnings per share for the ongoing year.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Sector Advanced Medical Equipment & Technology - NEC